Cardiac Magnetic Resonance Imaging in Patients With Newly Diagnosed Non-Hodgkin Lymphoma or Hodgkin Lymphoma Receiving Doxorubicin

• Status: Completed
• Trial end date: 2013-02-01
• Target enrollment: 0
• Participant gender: All

Summary

RATIONALE: Diagnostic procedures, such as cardiac magnetic resonance imaging, may help doctors detect early changes in the heart caused by chemotherapy.

PURPOSE: This clinical trial is studying how well cardiac magnetic resonance imaging works in patients with newly diagnosed non-Hodgkin lymphoma or Hodgkin lymphoma receiving doxorubicin.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: University of Nebraska
• Collaborator: National Cancer Institute (NCI)
• Treatments: Doxorubicin; Liposomal doxorubicin

Criteria

DISEASE CHARACTERISTICS:

• Diagnosis of non-Hodgkin lymphoma or Hodgkin lymphoma

• Newly diagnosed disease

• Planning to receive doxorubicin hydrochloride-based chemotherapy solely at the University of Nebraska Medical Center

PATIENT CHARACTERISTICS:

• Not pregnant or nursing

• Fertile patients must use effective contraception

• No pacemaker

• No chronic kidney disease stages 3-5 (glomerular filtration rate < 60 mL/min)

• Able to lie flat for 90 minutes

• No metallic foreign body not approved for MRI

• No known hypersensitivity to gadolinium contrast or other required drugs in the study

• No comorbidity or condition which, in the opinion of the investigator, may interfere with the assessments and procedures of this study

• Able to fulfill the requirements of the study

PRIOR CONCURRENT THERAPY:

• See Disease Characteristics

• No prior chemotherapy

• No prior radiotherapy to mantle or mediastinum